Skip to main content
    S

    Stereotaxis Inc (STXS)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • AMEX

    $0.81
    -0.04 (-4.48%)

    Market Cap: $85.02M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Stereotaxis Inc (STXS) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Stereotaxis (STXS) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Stereotaxis reported EPS of -$0.07, below the -$0.05 estimate. It beat the EPS estimate in 1 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    19%(5/27)
    Avg Surprise
    -12.25%

    Upcoming Estimates

    Reports Mar 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.05
    Range-$0.05 - -$0.04
    5 analysts
    Revenue Consensus
    $8.91M
    Range$7.84M - $9.55M
    5 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.02
    Range-$0.02 - -$0.02
    1 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.03+33.3%
    60d ago-$0.03+33.3%
    30d ago-$0.03+33.3%
    7d ago-$0.03+33.3%
    Current-$0.02
    Revenue Consensus
    $9.50M
    Range$9.50M - $9.50M
    2 analysts

    Next Report

    STXS has an expected report date of Mar 8, 2027.

    STXS Earnings Call

    The latest STXS earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    Earnings History

    Of the 27 quarters below that had an estimate, STXS beat 5, missed 13 and matched 9. Revenue for the quarter ended Sep 30, 2026 was $8.93M, up 19.7% from $7.46M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.07-$0.05-$0.06 - -$0.05-40.00%MissN/A20 up, 1 downNov 10, 2026$8.93M
    Jun 30, 2026-$0.05-$0.03-$0.06 - -$0.03-66.67%MissN/A31 up, 0 downAug 11, 2026$7.67M
    Mar 31, 2026-$0.06-$0.06-$0.06 - -$0.04-10.05%MissN/A31 up, 0 downMay 12, 2026$6.29M
    Dec 31, 2025-$0.06-$0.06-$0.07 - -$0.060.00%In lineN/A4N/AMar 9, 2026$8.64M
    Sep 30, 2025-$0.07-$0.06-$0.07 - -$0.05-16.67%MissN/A40 up, 0 downNov 11, 2025$7.46M
    Jun 30, 2025-$0.05-$0.07-$0.08 - -$0.05+28.57%BeatN/A41 up, 0 downAug 7, 2025$8.80M
    Mar 31, 2025-$0.07-$0.07-$0.09 - -$0.060.00%In lineN/A40 up, 3 downMay 12, 2025$7.47M
    Dec 31, 2024-$0.09-$0.07-$0.08 - -$0.04-38.46%MissN/A40 up, 2 downMar 3, 2025$6.34M
    Sep 30, 2024-$0.08-$0.05-$0.07 - -$0.03-60.00%MissN/A40 up, 0 downNov 11, 2024$9.20M
    Jun 30, 2024-$0.07-$0.05-$0.08 - -$0.04-40.00%MissN/A40 up, 0 downAug 12, 2024$4.50M
    Mar 31, 2024-$0.06-$0.06-$0.07 - -$0.060.00%In lineN/A50 up, 0 downMay 13, 2024$6.88M
    Dec 31, 2023-$0.07-$0.07-$0.07 - -$0.060.00%In lineN/A50 up, 0 downMar 4, 2024$4.57M
    Sep 30, 2023-$0.07-$0.06-$0.07 - -$0.05-16.67%MissN/A50 up, 0 downNov 9, 2023$7.80M
    Jun 30, 2023-$0.07-$0.07-$0.09 - -$0.050.00%In lineN/A50 up, 0 downAug 10, 2023$7.86M
    Mar 31, 2023-$0.07-$0.06-$0.07 - -$0.04-16.67%MissN/A40 up, 0 downMay 9, 2023$6.55M
    Dec 31, 2022-$0.06-$0.07-$0.08 - -$0.04+14.29%BeatN/A60 up, 0 downMar 3, 2023$7.30M
    Sep 30, 2022-$0.07-$0.06-$0.07 - -$0.05-16.67%MissN/A80 up, 0 downNov 10, 2022$7.66M
    Jun 30, 2022-$0.07-$0.06N/A-16.67%MissN/AN/A0 up, 0 downAug 9, 2022$6.15M
    Mar 31, 2022-$0.06-$0.06-$0.08 - -$0.040.00%In lineN/A60 up, 0 downMay 10, 2022$7.04M
    Dec 31, 2021-$0.05-$0.05-$0.07 - -$0.030.00%In lineN/A6N/AMar 3, 2022$8.24M
    Sep 30, 2021-$0.07-$0.04-$0.07 - -$0.02-75.00%MissN/A31 up, 0 downNov 11, 2021$9.11M
    Jun 30, 2021-$0.05-$0.03-$0.04 - -$0.02-66.67%MissN/A4N/AAug 10, 2021$9.05M
    Mar 31, 2021-$0.02-$0.03-$0.03 - -$0.02+33.33%BeatN/A3N/AMay 10, 2021$8.62M
    Dec 31, 2020-$0.02-$0.03-$0.04 - -$0.02+33.33%BeatN/A3N/AFeb 25, 2021N/A
    Sep 30, 2020-$0.03-$0.03-$0.05 - -$0.020.00%In lineN/A3N/ANov 9, 2020$17.41M
    Jun 30, 2020-$0.03-$0.05-$0.05 - -$0.05+40.00%BeatN/A2N/AAug 6, 2020$5.35M
    Mar 31, 2020-$0.03-$0.03-$0.03 - -$0.030.00%In lineN/A2N/AMay 5, 2020$5.76M
    Dec 31, 2019-$0.02N/AN/AN/AN/AN/AN/AN/AMar 10, 2020N/A
    Sep 30, 2019$0.00N/AN/AN/AN/AN/AN/AN/ANov 14, 2019$8.20M
    Jun 30, 2019-$0.03N/AN/AN/AN/AN/AN/AN/AAug 8, 2019$13.35M
    Mar 31, 2019-$0.04N/AN/AN/AN/A-500.0%N/AN/AMay 9, 2019$7.00M
    Dec 31, 2018-$0.02N/AN/AN/AN/AN/AN/AN/AMar 12, 2019$7.27M
    Sep 30, 2018-$0.01N/AN/AN/AN/AN/AN/AN/ANov 12, 2018$7.56M
    Jun 30, 2018-$0.02N/AN/AN/AN/A-300.0%N/AN/AAug 7, 2018$7.55M
    Mar 31, 2018$0.01N/AN/AN/AN/A0.0%N/AN/AMay 14, 2018$6.97M
    Dec 31, 2017-$0.13N/AN/AN/AN/A-155.6%N/AN/AMar 6, 2018$7.56M
    Sep 30, 2017-$0.21N/AN/AN/AN/AN/AN/AN/ANov 9, 2017$8.14M
    Jun 30, 2017$0.01N/AN/AN/AN/AN/AN/AN/AAug 10, 2017$8.47M
    Mar 31, 2017$0.01N/AN/AN/AN/AN/AN/AN/AMay 8, 2017$6.98M
    Dec 31, 2016$0.23N/AN/AN/AN/AN/AN/AN/AMar 16, 2017$7.31M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.25, after -$0.30 the year before. It was -$0.54 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.25N/A
    Dec 31, 2024-$0.30N/A
    Dec 31, 2023-$0.28N/A
    Dec 31, 2022-$0.26N/A
    Dec 31, 2021-$0.19N/A
    Dec 31, 2020-$0.11N/A
    Dec 31, 2019-$0.09N/A
    Dec 31, 2018-$0.04N/A
    Dec 31, 2017-$0.32N/A
    Dec 31, 2016-$0.54N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 4,800 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q1Mar 31, 20264,7566
    2025Q4Dec 31, 20256,3838
    2025Q3Sep 30, 20253,8847
    2025Q2Jun 30, 20253,2305
    2025Q1Mar 31, 20256,1997
    2024Q4Dec 31, 20246,1976
    2024Q3Sep 30, 20245,5007
    2024Q2Jun 30, 20247,0816

    2026Q1 Earnings Call

    Opening remarks

    David Leo Fischel Chairman and CEO It is now my pleasure to turn the floor over to your host, David Leo Fischel, chairman and CEO of Stereotaxis. Thank you, operator, and good afternoon, everyone. Stereotaxis has had an amazing start to this year. While our reported quarterly numbers do not yet reflect it, we are going through one of the most exciting periods in Stereotaxis' history, given the amount of progress, the initial commercial green shoots of success, and the clarity on the opportunity ahead of us. These give us confidence in our overall vision reaching a new level of maturity in our near-term and long-term growth. In my prepared remarks, I will touch upon the key areas of progress, the commercial green shoots, and the opportunities ahead of us. Kimberly will then review our first-quarter results, and we will open the line to questions. The most notable achievement of the past year has been a string of regulatory approvals in the U.S. and Europe for an entirely new foundational ecosystem of products. While Stereotaxis has a long history, our clinical and commercial experience is nearly all with first-generation technology from twenty years ago. After spending the past eight years and over $75 million rebuilding an R&D pipeline, we brought to market an entirely new foundation of products. In just the past few months, we received four U.S. FDA regulatory approvals: for a complex surgical robot, robotically steered therapeutic and diagnostic catheters, and a digital surgery cockpit. Outside of the U.S., we received multiple approvals in Europe and China. These product approvals are not just incremental innovations, but rather they structurally change our opportunity. We essentially developed a fresh new start-up company on the shoulders of our legacy technology and funded by our legacy business. The streak of regulatory success that began last year continued in the first part of this year, with two essential FDA approvals. First, in January, we received PMA approval for the MAGIC cardiac ablation catheter. Then just last month, we received FDA clearance for Synchrony, our digital surgery cockpit that introduces connectivity and intelligence to the operating room. MAGIC is Stereotaxis' first proprietary therapeutic catheter and is the first ablation catheter ever to be approved by the FDA specifically for arrhythmia patients with complex congenital heart disease. The catheter strategically allows us to overcome our historical dependency on Johnson & Johnson, and to participate robustly in the recurring revenue of each procedure. Following regulatory approval, we recently announced that we began first MAGIC procedures at multiple U.S. hospitals. Those procedures have gone well.

    Frequently Asked Questions About STXS

    When is Stereotaxis's next earnings date?

    Stereotaxis's next earnings report is expected for Mar 8, 2027.

    Did STXS beat earnings estimates last quarter?

    No. Stereotaxis reported EPS of -$0.07 for the quarter ended Sep 30, 2026, below the -$0.05 estimate by 40.00%.

    What EPS do analysts expect from STXS next quarter?

    The consensus EPS estimate for Stereotaxis for the quarter ending Dec 31, 2026 is -$0.05 from 5 analysts, with estimates from -$0.05 to -$0.04.

    How often does STXS beat earnings estimates?

    Stereotaxis beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -17.91%.